Original filing text · Part I

Item 3 — Quantitative and Qualitative Disclosures About Market Risk

Bioventus Inc. · 10-Q · Q2 FY2026 · Period ended Jun 27, 2026

This is the extracted source text from the SEC filing. Formatting may differ from the original document.

There have been no material changes to our market risks as disclosed in our 2025 10-K. 34 Table of Contents